|
|
||||||||
|
REVIEW |
P Vigneri, Department of Biomedical Sciences, Section of General Pathology, University of Catania, Catania, Italy
F Frasca, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
L Sciacca, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
G Pandini, Department of Internal and Specialistic Medicine, Section of Endocrinology, University of Catania, Catania, Italy
R Vigneri, Internal Medicine, Endocrinology, Catania, 95122, Italy
Correspondence: Riccardo Vigneri, Email: vigneri{at}unict.it
Abstract
Diabetes and Cancer are two heterogeneous, multifactorial, severe and chronic diseases. Because of their frequency, reciprocal influences, even if minor, may have a major impact.
Epidemiological studies clearly indicate that the risk for several types of cancer (including pancreas, liver, breast, colorectal, urinary tract and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased.
Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with preeminent metabolic but also mitogenic effects and its action in malignant cells is favored by mechanisms acting both at the receptor and post-receptor level. Obesity, hyperglycemia and increased oxidative stress may also contribute to increased cancer risk in diabetes.
While antidiabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and antiandrogens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors.
In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.
This article has been cited by other articles:
|
R. Vigneri, L. Sava, S. Squatrito, and L. Sciacca Comment on: Yang et al. (2010) Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry. Diabetes;59:1254-1260 Diabetes, November 1, 2010; 59(11): e24 - e24. [Full Text] [PDF] |
||||
|
M. Toi, Y. Ohashi, A. Seow, T. Moriya, G. Tse, H. Sasano, B. W. Park, L. W. C. Chow, A. V. Laudico, C. H. Yip, et al. The Breast Cancer Working Group Presentation was Divided into Three Sections: The Epidemiology, Pathology and Treatment of Breast Cancer Jpn. J. Clin. Oncol., September 1, 2010; 40(suppl_1): i13 - i18. [Abstract] [Full Text] [PDF] |
||||
|
E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee Diabetes and Cancer: A consensus report Diabetes Care, July 1, 2010; 33(7): 1674 - 1685. [Full Text] [PDF] |
||||
|
E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee Diabetes and Cancer: A Consensus Report CA Cancer J Clin, July 1, 2010; 60(4): 207 - 221. [Abstract] [Full Text] [PDF] |
||||
|
K. Hemminki, X. Li, J. Sundquist, and K. Sundquist Risk of Cancer Following Hospitalization for Type 2 Diabetes Oncologist, June 1, 2010; 15(6): 548 - 555. [Abstract] [Full Text] [PDF] |
||||
|
H. C. Gerstein Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers? JAMA, February 3, 2010; 303(5): 446 - 447. [Full Text] [PDF] |
||||
|
C. R. Chong and B. A. Chabner Mysterious Metformin Oncologist, December 1, 2009; 14(12): 1178 - 1181. [Full Text] [PDF] |
||||
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |